Search research articles
Contact Us
Filters
Showing results (331-340 of 349) with videos related to
Page
of 35
Sort By:
Cancer Research
|
July 1, 1988
A phase I study of recombinant interleukin 2 plus recombinant beta-interferon
R L Krigel, K A Padavic-Shaller, A R Rudolph, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
May 15, 1992
Lung injury after deposition of IgA immune complexes. Requirements for CD18 and L-arginine
M S Mulligan, J S Warren, C W Smith, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
July 1, 1988
Specificity of tumor necrosis factor toxicity for human mammary carcinomas relative to normal mammary epithelium and correlation with response to doxorubicin
C Dollbaum, A A Creasey, S H Dairkee, et al.
Journal of the American Academy of Child and Adolescent Psychiatry
|
March 23, 2005
Steady-state pharmacokinetics of bupropion SR in juvenile patients
W Burleson Daviss, James M Perel, George R Rudolph, et al.
Therapeutic Drug Monitoring
|
April 22, 2006
Acute antidepressant response and plasma levels of bupropion and metabolites in a pediatric-aged sample: an exploratory study
W Burleson Daviss, James M Perel, David A Brent, et al.
American Journal of Human Genetics
|
June 12, 1999
A gene for inherited cutaneous venous anomalies ("glomangiomas") localizes to chromosome 1p21-22
L M Boon, P Brouillard, A Irrthum, et al.
Protein Engineering
|
January 1, 1992
Biochemical properties of the kringle 2 and protease domains are maintained in the refolded t-PA deletion variant BM 06.022
U Kohnert, R Rudolph, J H Verheijen, et al.
Psychopharmacology Bulletin
|
January 1, 1996
Venlafaxine for panic disorder: results from a double-blind, placebo-controlled study
M H Pollack, J J Worthington, M W Otto, et al.
Structure (London, England : 1993)
|
November 15, 1996
Enzyme flexibility, solvent and 'weak' interactions characterize thrombin-ligand interactions: implications for drug design
R A Engh, H Brandstetter, G Sucher, et al.
Transplantation Proceedings
|
April 1, 1996
Continuous complement (C) inhibition using soluble C receptor type 1 (sCR1): effect on hyperacute rejection (HAR) of pig-to-primate cardiac xenografts
S k Pruitt, R R Bollinger, B H Collins, et al.
Page
of 35
Search research articles
Search
Showing results (331-340 of 349) with videos related to
Sort By:
Page
of 35
Cancer Research
|
July 1, 1988
A phase I study of recombinant interleukin 2 plus recombinant beta-interferon
R L Krigel, K A Padavic-Shaller, A R Rudolph, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
May 15, 1992
Lung injury after deposition of IgA immune complexes. Requirements for CD18 and L-arginine
M S Mulligan, J S Warren, C W Smith, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
July 1, 1988
Specificity of tumor necrosis factor toxicity for human mammary carcinomas relative to normal mammary epithelium and correlation with response to doxorubicin
C Dollbaum, A A Creasey, S H Dairkee, et al.
Journal of the American Academy of Child and Adolescent Psychiatry
|
March 23, 2005
Steady-state pharmacokinetics of bupropion SR in juvenile patients
W Burleson Daviss, James M Perel, George R Rudolph, et al.
Therapeutic Drug Monitoring
|
April 22, 2006
Acute antidepressant response and plasma levels of bupropion and metabolites in a pediatric-aged sample: an exploratory study
W Burleson Daviss, James M Perel, David A Brent, et al.
American Journal of Human Genetics
|
June 12, 1999
A gene for inherited cutaneous venous anomalies ("glomangiomas") localizes to chromosome 1p21-22
L M Boon, P Brouillard, A Irrthum, et al.
Protein Engineering
|
January 1, 1992
Biochemical properties of the kringle 2 and protease domains are maintained in the refolded t-PA deletion variant BM 06.022
U Kohnert, R Rudolph, J H Verheijen, et al.
Psychopharmacology Bulletin
|
January 1, 1996
Venlafaxine for panic disorder: results from a double-blind, placebo-controlled study
M H Pollack, J J Worthington, M W Otto, et al.
Structure (London, England : 1993)
|
November 15, 1996
Enzyme flexibility, solvent and 'weak' interactions characterize thrombin-ligand interactions: implications for drug design
R A Engh, H Brandstetter, G Sucher, et al.
Transplantation Proceedings
|
April 1, 1996
Continuous complement (C) inhibition using soluble C receptor type 1 (sCR1): effect on hyperacute rejection (HAR) of pig-to-primate cardiac xenografts
S k Pruitt, R R Bollinger, B H Collins, et al.
Page
of 35